Jobst Technologies unveils new branding as iST Jobst
12. November 2025
By November 2025, a new chapter has been marked in the evolution of Jobst Technologies GmbH with the introduction of a refreshed brand identity. Under a joint logo and unified
By November 2025, a new chapter has been marked in the evolution of Jobst Technologies GmbH with the introduction of a refreshed brand identity. Under a joint logo and unified
Last week Jens Ebnet from Ebnet Medical visited us to form a joint vision for the future of metabolic monitoring and safe, reliable venous access* for hospitalized patients. We believe
In May 2025 we sucessfully exhibited at TERMIS 2025 in our hometown Freiburg, Germany! This engaging event brought together the tissue engineering and regenerative medicine community from Universities, R&D groups
Will cell and gene therapy (CGT) manufacturing inevitably move to small batch and single dose production?How can we ensure sustainable manufacturing and make these life-saving therapies available for more patients
Biosensor Support Grant for CGT projects by Jobst Technologies GmbH In Cell and Gene Therapy (CGT) development and manufacturing excessive needs are placed on repeatability, safety and quality, as well as on process stability. During production crucial insights
